BJL
MYGN icon

Brighton Jones LLC’s Myriad Genetics MYGN Stock Holding History

Brighton Jones LLC’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107K Buy
+18,760
New +$85.2K ﹤0.01% 1307

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Brighton Jones LLC's MYGN Position: Q2 2026 in Review

Brighton Jones LLC opened a new position in Myriad Genetics (MYGN) in Q2 2026: 18,760 shares worth $107K. The stake represents ﹤0.01% of the portfolio and ranks #1307 among its holdings.

80 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Brighton Jones LLC held 18,760 shares of Myriad Genetics worth $107K as of Q2 2026.
  • Myriad Genetics was a new Brighton Jones LLC position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1307 holding.
  • 80 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.